Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Journal: Open forum infectious diseases
Published: January 26, 2023
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.
Journal: Scientific reports
Published: December 21, 2022
Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database.
Journal: BMJ open
Published: December 19, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Journal: JAMA network open
Published: August 15, 2022
Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19.
Journal: Infectious diseases and therapy
Published: July 19, 2022
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Journal: Nature medicine
Published: May 23, 2022
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: April 26, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
Journal: The Journal of infectious diseases
Published: April 22, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Infectious diseases
Published: April 04, 2022
Last Updated: 09/26/2026